Skip to main content

Table 1 Clinical characteristics and antimicrobial treatment of patients with Mycoplasma pneumoniae pneumonia (MPP), CAP due to other bacterial pathogens, and CAP with unknown etiology

From: Mycoplasma pneumoniaepneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ)

Variable CAP due to other definite bacterial pathogens
n = 621
p1 MPP n = 307 p2 CAP with no known bacterial etiology n = 3604
Age ( ± SD) 61 ± 17 years .000 41 ± 16 years .000 61 ± 18 years
Male gender 58% .000 41% .000 56%
Outpatient/hospitalized 22%/78% .000 56%/44% .000 36%/64%
CRB 65 Score
0-1-2-3-4 (%)
33-46-16-4-1 .000 72-25-3-0.4-0 .000 39-43-15-2-0.4
Packyears( ± SD) 32 ± 25 .000 15 ± 14 .000 29 ± 23
Pleural effusion 17% .000 6% .001 13%
Dyspnoea 80% .000 69% ns 72%
Pleural pain 47% .000 34% ns 42%
Confusion 11% .000 2% .001 8%
Oxygen requirement 57% .000 25% .000 41%
Malignancy 9% .000 2% .000 10%
Chronic respiratory disease 38% .000 20% .000 36%
Renal insufficiency 8% .001 2% .000 8%
Congestive heart failure 19% .000 4% .000 19%
Diabetes 20% .000 3% .000 16%
Respiratory sample obtained* 42% .000 58% .000 30%
Leucocytes (median)/μl 13 200 .000 8850 .000 11 000
CRP (median) mg/l 173 .000 60 .001 73
Duration of antibiotic therapy
( ± SD)
13 ± 6 days .000 11 ± 4 days ns 11 ± 5 days
LOS in hospitalized patients
( ± SD)
14 ± 11 days .000 9 ± 5 days .000 12 ± 9 days
Deaths within 30 days 54 (8.7%) .000 2 (0.7%) .000 234 (6.5%)
  1. Patients with Mycoplasma pneumonia (MPP) were compared to patients with CAP due to other bacterial pathogens (p values marked as p1) and patients with CAP with unknown etiology (p values marked as p2), respectively. The significance level was set at < .001. (*) samples were available for standardized examination in the CAPNETZ central study unit. SD = standard deviation ns = not significant